Skip to content

Total debt at other companies

Immunome logo
ImmunomeIMNM
$3.69M-22.6%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$419K+204%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$113M+88.3%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$350.49M+4.2%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Pfizer logo
PfizerPFE

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Calculated from Nuvation Bio’s reported figures.

Plus components not separately reported this period.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's total debt?
Nuvation Bio (NUVB) reported total debt of $57.15M in Q1 2026.
How has Nuvation Bio's total debt changed year-over-year?
Nuvation Bio's total debt increased by 400.8% year-over-year, from $11.41M to $57.15M.
What is the long-term trend for Nuvation Bio's total debt?
Over 5 years (2020 to 2025), Nuvation Bio's total debt has grown at a 69.5% compound annual growth rate (CAGR), from $4.1M to $57.36M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.